Revvity Inc. reported fourth‑quarter 2025 results with revenue of $772.06 million, up 5.9% year‑over‑year, and adjusted earnings per share of $1.70, beating the consensus estimate of $1.63 by $0.07. GAAP earnings per share were $0.87 versus $0.78 a year earlier. The earnings beat was driven by disciplined cost management and a favorable product mix that lifted operating income to $229 million, a 20% increase from the prior year.
Diagnostics revenue reached $390 million, growing 7% organically, while Life Sciences revenue held steady at $382 million. Software and reagent sales contributed to margin expansion, allowing the company to post an operating margin of 29.7% in Q4 versus 30.3% in the same quarter of 2024. The margin contraction was largely attributable to ongoing investments in the Diagnostics platform and a shift toward higher‑margin software contracts.
Full‑year 2025 figures showed total revenue of $2.856 billion, a 3.7% increase from $2.755 billion in 2024, and adjusted EPS of $5.06 versus $4.90 a year earlier. Operating income for the year was $773 million, supporting a 27.1% operating margin. The results were underpinned by the acquisition of ACD/Labs, which added roughly $20 million in revenue and about 75 basis points to margins, and by the continued rollout of the Signals Synthetica AI platform.
Management raised its 2026 outlook, projecting full‑year revenue of $2.96 billion to $2.99 billion—an increase from the prior guidance of $2.90 billion to $2.95 billion—and adjusted EPS of $5.35 to $5.45, up from $5.25 to $5.35. The upward revision reflects confidence in sustained demand for integrated diagnostics workflows and the growing Signals software franchise. CEO Prahlad Singh noted that the company is “well positioned as we enter 2026,” while CFO Max Grykowiak emphasized a focus on strong free‑cash‑flow conversion.
Investor reaction was mixed. While the EPS beat and raised guidance were welcomed, concerns about margin compression—stemming from investments and a shift in product mix—and modest revenue growth tempered enthusiasm. Analysts highlighted the company’s ability to maintain profitability amid headwinds such as DRG‑related volume pressures in China, tariff impacts, and foreign‑exchange fluctuations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.